The majority of men with progressive prostate cancer develop metastases with the skeleton being the most prevalent metastatic site. Unlike many other tumors that metastasize to bone and form osteolytic lesions, prostate carcinomas form osteoblastic lesions. However, histological evaluation of these lesions reveals the presence of underlying osteoclastic activity. These lesions are painful, resulting in diminished quality of life of the patient. There is emerging evidence that prostate carcinomas establish and thrive in the skeleton due to cross-talk between the bone microenvironment and tumor cells. Bone provides chemotactic factors, adhesion factors, and growth factors that allow the prostate carcinoma cells to target and proliferate in the skeleton. The prostate carcinoma cells reciprocate through production of osteoblastic and osteolytic factors that modulate bone remodeling. The prostate carcinoma-induced osteolysis promotes release of the many growth factors within the bone extracellular matrix thus further enhancing the progression of the metastases. This review focuses on the interaction between the bone and the prostate carcinoma cells that allow for development and progression of prostate carcinoma skeletal metastases.
Introduction
Prostate carcinoma is the most frequently diagnosed cancer in men and the second leading cause of cancer death among men in the United States [1] . The most common site of prostate carcinoma metastasis is the bone with skeletal metastases identified at autopsy in up to 90% of patients dying from prostate carcinoma [2] [3] [4] . Skeletal metastasis results in significant complications that diminish the quality of life in affected patients. These complications include bone pain, impaired mobility, pathological fracture, spinal cord compression and symptomatic hypercalcemia [5] [6] [7] . Despite advances in the diagnosis and management of prostate carcinoma, advanced disease with skeletal metastasis remains incurable. Current therapeutic modalities are mostly palliative, and include hormonal therapy, pharmacological management of bone pain, radiotherapy for pain and spinal cord compression [8] , various chemotherapy regimens, and the use of bisphosphonates to inhibit osteoclast activity [9] . In spite of the severe complications of prostate carcinoma skeletal metastasis, there have not been many advances in the therapeutic arena to prevent or diminish these lesions. It is critical that a solid understanding of the pathophysiology of prostate carcinoma skeletal metastatic process is developed to provide the basis for creating strategies to prevent or diminish their occurrence and associated complications. A preponderance of evidence suggests that establishment and progression of prostate carcinoma bone metastases is dependent on interaction between the bone microenvironment and the prostate carcinoma cell through both soluble and cell-membrane bound bioactive factors. In this review, we will summarize some of the cross-talk mechanisms between bone and prostate carcinoma.
The effects of bone on prostate carcinoma metastasis
In agreement with the 'seed and soil' theory of metastases espoused by Paget [10] , the predilection of prostate carcinoma to establish metastases in bone as opposed to other organs suggests that the bone microenvironment offers a fertile soil for prostate carcinoma growth. Prior to interacting on the bone cells and bone matrix, the prostate carcinoma cells must enter the bone compartment. This is accomplished by several general mechanisms that include chemotaxis from the circulation, attachment to bone endothelium, extravasation, and invasion. The bone microenvironment is a complicated mixture of mineralized and non-mineralized bone matrix and endothelial, hematopoietic, immune, and bone marrow stromal cells. Each of these components of the bone microenvironment may contribute to the establishment of prostate carcinoma metastases through provision of chemotactic, angiogenic, adhesion and growth factors.
Chemotaxis
When prostate carcinoma cells are injected adjacent to adult human bone implanted in SCID mice, the prostate carcinoma cells to migrate to adult human bone [11] . This observation provides evidence that bone provides chemotactic factors for prostate carcinoma cells. This is further supported by the observation that bone undergoing active resorption facilitated adhesion [12] and chemotaxis [13, 14] of tumor cells to bone compared to non-resorbing bone. Collagen products appear to be one component of bone that induces tumor chemotaxis [15] . The factors through which bone induces chemotaxis are not clear. However, low glycosylated osteonectin was found to be an active chemotaxic factor in crude bone extracts that promoted chemotaxis of human prostate epithelial cells and increased the invasive ability of human prostate carcinoma cells [16] . In contrast with this observation, purified fibronectin, but not crude bone extracts induced migration of the prostate carcinoma DU-145 cell line [17] . Cell line specificity may account for these differences. Epidermal growth factor induced migration of the TSU-pr1 prostate carcinoma cell line [18] . Since EGF is present in medullary bone, this observation suggests that it may act as a chemotactic factor for bone metastases. Finally, the Rho-kinase inhibitor, Y-27632, inhibited in vitro chemotactic migration to bone marrow fibroblast conditioned media and metastatic growth in immune-compromised mice of highly invasive human prostatic cancer (PC3) cells [19] . This observation suggests that modulation of kinase activity may prove fruitful in inhibition of skeletal metastasis. In addition to the above substances, which typically are not considered chemotactic factors, prostate carcinoma cells may commandeer the normal leukocyte bone marrow homing mechanism using the chemokine pathway [20] . Chemokines are classified based upon the relative position of cysteine residues near the NH2-terminus into four major families: CC,CXC,C,CX 3 C (as reviewed in [21] ). Chemokines activate receptors that are members of the large family of seven-transmembrane G protein-coupled proteins. In addition to the role that chemokines have in cell migration, they play significant roles in normal development, inflammation, atherosclerosis and angiogenesis. The rapidly increasing knowledge of chemokines has begun to impact many aspects of tumor biology including modulation of proliferation, angiogenesis and immune response to tumor (as reviewed in [22] ).
An important role for chemokines may be to regulate metastatic behavior. Localization in tissues and migration to target organs are essential steps in the pathobiology of metastasis which strongly support the analogy to hematopoietic cell homing. In this context, the CXC chemokine stromal-derived factor (SDF-1; CXCL12) and its receptor, CXCR4 appear to be critical molecular determinants for these events [23, 24] . This has been substantiated in gene knockout investigations [25, 26] and by the demonstration that level of CXCR4 expression correlates with the ability of human hematopoietic progenitors to engraft into nude mice [26] . In the bone marrow, SDF-1 is constitutively produced by osteoblasts, fibroblasts and endothelial cells [27] . However, not all vascular endothelial cells express SDF-1, suggesting that organ-specific expression SDF-1 may account for the selectivity of metastases to target certain organs [28] .
Several lines of evidence suggest that SDF-1 contributes to the pathogenesis of prostate carcinoma metastases. Inhibition of chemokines diminished in vitro proliferation of PC-3 cells [29] and anti-CXCR2 antibody inhibited IL-8-stimulated migration of PC-3 cells in vitro [30] . These studies suggest that chemokines contribute to prostate metastatic pathophysiology. This possibility is reinforced by the observation that CXCR4 is expressed in normal prostate tissues, albeit at low levels [31] , as well as several neoplasms that invade the marrow (e.g., breast cancers, Burkitt's lymphoma, leukemias) [31] [32] [33] . Furthermore, several prostate carcinoma cell lines express CXCR4 mRNA, and SDF-1 increased migration of these cells in vitro [34] . It was recently demonstrated that normal breast tissues express little CXCR4, whereas breast neoplasms express high levels of CXCR4 [35, 36] , and antibody to CXCR4 blocked the metastatic spread of the tumors to the bone in an experimental metastasis model [35] . Taken together, these data suggest that SDF-1 and CXCR4 are likely critical regulators of prostate carcinoma metastasis to bone.
Attachment to endothelium
Cell adhesion plays a vital role in cancer metastasis. In fact, the ability of cancer cells to adhere to organ-specific cells and components may be a critical regulator of their metastatic pattern. A cancer cell in the circulation initially interacts with the organ's microvascular endothelium and subsequently the organ's extracellular matrix (ECM) components [37, 38] . Cell adhesion molecules (CAMs) expressed on both the cancer and endothelial cells mediate these interactions. CAMs expressed on the endothelial cells are regulated by an organ's microenvironment, which results in CAM expression specific to each organ [39] . The organ-specific composition of ECM proteins such as laminin, fibronectin, and vitronectin that are recognized by CAMs expressed on cancer cells contribute significantly to organ-specific metastasis [40, 41] .
It has been proposed that prostate carcinoma metastasis to bone is mediated, in part, by preferential adhesion to bone marrow endothelium as opposed to endothelium from other sites [42, 43] . Two studies demonstrated that prostate carcinoma cells adhered preferentially to immortalized human bone marrow endothelial (HBME) cells as compared to human umbilical vein endothelial cells (HUVEC), immortalized human aortic endothelial cells (HAEC-I), and immortalized human dermal microvascular endothelial cells (HDMVEC) [42, 44] . This observation was confirmed in another study that demonstrated preferential adhesion of PC-3 cells to HBME cells as compared to HUVECs and lung endothelial cells, Hs888Lu [45] . Interestingly, this adhesion was enhanced when HBME cells were grown on bone ECM components [44] . The PC-3 cell line was used as a model for prostate carcinoma in these studies because it was derived from a bone metastasis. To determine the CAMs involved in prostate carcinoma (PC)-HBME interaction, galactose-rich-modified citrus pectin (MCP) and several antibodies to known CAMs expressed on HBME cell monolayers, were used in adhesion assays. MCP was used because it was reported to interfere with interactions mediated by carbohydratebinding proteins such as galectins [46] . The data demonstrated that MCP and antibodies to galectin-3, vascular cell adhesion molecule (VCAM), CD11a (alpha-L), CD18 (beta-2), and leukocyte functional antigen-1 (LFA-1) pectin, reduced PC-3 cell adhesion to HBME cell monolayers [42] . This observation suggests that carbohydrate-binding proteins, VCAM, alpha-L, beta-2, and LFA-1 may be partially involved in prostate carcinoma cell adhesion to HBME cells. Beta-1 integrins expressed on HUVEC were demonstrated to mediate PC-3 cell adhesion to this endothelial cell line [47] . Surprisingly, the beta-1 integrins expressed on HBME cells were not involved in PC-3 cell adhesion to HBME cell monolayers [48] ; however, beta-1 integrins, expressed on PC-3 cells, did mediate its interaction with HBME cell monolayers [45] . Hyaluronan and galactosyl receptor, a cell surface C-type lectin expressed on PC-3 cells, were also shown to mediate PC-HBME interaction [49, 50] .
The ability of metastatic prostate cells to adhere to the bone matrix may also contribute to prostate carcinoma frequent metastasis to bone matrix [51, 52] . Kostenuik demonstrated that PC-3 cells adhered to the collagen type I in the bone matrix. This adhesion was mediated by α2β1 expressed on PC-3 cells and was upregulated by transforming growth factor-β (TGF-β), a major bone-derived cytokine [53] . Festuccia and colleagues [52] showed that osteoblast-conditioned media containing TGF-β, modulated the PC-3 interaction with ECM proteins, including collagen type I. These results provide evidence that TGF-β, present in the bone marrow, can influence prostate carcinoma cell adhesion to the bone matrix by modulating surface expression of selected integrins.
Growth factors
The calcified bone matrix is replete with putative prostate carcinoma growth factors including insulinlike growth factors (IGF), bone morphogenetic proteins (BMP), fibroblast growth factors (FGF) and transforming growth factor (TGF)-beta, which are released upon resorption of bone [54, 55] . Furthermore, experimental evidence that resorption of calcified bone matrix promotes tumor growth was suggested by the observation that conditioned media for bone cultures undergoing resorption stimulated cancer cell growth of a variety of tumor cell lines [56] . Taken together, these data suggest that inhibiting bone resorption will diminish cancer growth by decreasing growth factors availability in the bone microenvironment.
Several [64] [65] [66] . As research continues on the extracellular matrix of bone, it is very likely that additional prostate carcinoma growth factors will be discovered.
3. The effect of prostate carcinoma on the bone: Osteoblastic
Prostate skeletal metastases are mixed osteoblastic and osteolytic lesions
Once in the bone, prostate carcinoma tumors have pathobiology that appears to be somewhat unique to cancer skeletal metastases. Specifically, prostate carcinoma skeletal metastases are most often characterized as osteoblastic (i.e., increased mineral density at the site of the lesion) as opposed to osteolytic. Other tumors, such as breast cancer, can form osteoblastic lesions; however, these occur less frequently [67, 68] . In spite of the radiographic osteoblastic appearance it is clear from histological evidence that prostate carcinoma metastases form a heterogeneous mixture of osteolytic and osteoblastic lesions although osteoblastic lesions predominate [69] [70] [71] [72] . Sites of prostate carcinoma bone metastases are often demonstrated to have increases in osteoid surface, osteoid volume, mineralization rates [73, 74] . Recent evidence shows that osteoblastic metastases form on trabecular bone at sites of previous osteoclastic resorption, and that such resorption may be required for subsequent osteoblastic bone formation [75, 76] . Clinical evidence demonstrates increased systemic markers of both bone production and bone resorption in prostate carcinoma patients [77, 78] in addition to bone histomorphometric findings of increased indices of bone resorption [71] . These findings suggest that prostate carcinoma induces bone production through an overall increase in bone remodeling, which in the non-pathologic state is a balance between osteoclastic resorption of bone and osteoblast-mediated replacement of resorbed bone (as reviewed in [79] [80] [81] ). In the case of prostate carcinoma, it appears the induction of osteoblast-mediated mineralization outweighs the increase in osteoclast resorption resulting in overall formation of osteoblastic lesions. The osteoblastic lesions result in overall weakening of the bone for the following reasons; mature, healthy bone is formed of lamellar bone, which allows for tight packing of collagen bundles and optimum bone strength. In contrast, prostate carcinoma induces production of woven bone, which is composed of loosely packed, randomly oriented collagen bundles that produce bone with suboptimal strength [82, 83] . Thus, the combination of underlying osteolysis and production of weak bone leads to a predisposition to fracture. The mechanisms through which prostate carcinoma cells promote bone mineralization remain poorly understood.
A variety of factors may contribute to prostate carcinoma-mediated bone mineralization
Prostate carcinoma produces osteoblastic factors that mediate their effect through activation of the osteoblast transcription factor Cbfa1 in the osteoblast precursor [84] . This suggests that induction of osteosclerosis occurs through normal osteoblast differentiation pathways. In addition to this observation, the prostate carcinoma cell itself demonstrates increased expression of Cbfa1 an the ability to mineralize in vitro, suggesting that it directly contributes to osteosclerosis [85] . Many factors that have direct or indirect osteogenic properties have been implicated in prostate carcinoma's osteogenic activity (Table 1 ) (as reviewed in [86, [87] [88] [89] ). Although, initially identified as a nondefined osteoblastic activity from prostate carcinoma cells in vitro [90] , many specific factors have been [99] Urinary plasminogen activator (urokinase) [235] identified that may promote osteoblastic lesions. Some of these factors, such as bone morphogenetic proteins (BMP) [91] [92] [93] and enodothlin-1 (ET-1) [94] may directly stimulate differentiation of osteoblast precursors to mature mineral-producing osteoblasts [95] or induce osteoblast protein production [93] . Other factors such as parathyroid hormone-related protein (PTHrP) may work through inhibition of osteoblast apoptosis [96, 97] . Additionally, there are proteins that may work indirectly to enhance bone production, such as the serine proteases, prostate specific antigen (PSA) and urinary plasminogen activator (uPA), which can activate latent forms of osteogenic proteins, such as transforming growth factor-β (TFG-β [98, 99] . Finally, some molecules, such as osteoprotegerin (OPG) [100] [101] [102] and ET-1 (in a dual role with its osteoblast-stimulating activity) [103] can enhance osteosclerosis through inhibiting osteoclastogenesis. Other tumor types, such as osteosarcoma, are also known to produce a variety of osteoblastic factors [104] [105] [106] . With such a large number of factors, it is difficult to determine which the key factor is, and most likely several of these osteogenic factors work in concert to produce maximal bone production.
Parathyroid hormone related protein (PTHrP)
PTHrP was originally identified as a tumor-derived factor responsible for humoral hypercalcemia of malignancy (HHM). It has limited homology with the endocrine hormone, parathyroid hormone, sharing 7 of the first 13 N-terminal amino acids, but otherwise is dissimilar and immunologically distinct [107] . PTH AND PTHrP bind to the same receptor (the PTH-1 receptor) and evoke the same biological activity due to similarities in their steric configurations at the region of 25-34 amino acids. Patients with solid tumors and hypercalcemia have increased serum PTHrP in 80% of the cases, emphasizing the impact of this peptide to increase bone resorption and renal tubular resorption of calcium [107] . Subsequent to its characterization in HHM, PTHrP was found to be produced by many normal tissues including, epithelium, lactating mammary gland, and cartilage where it has an autocrine, paracrine, or intracrine role [107] . PTHrP plays a critical role in the development of the skeleton as evidenced by its lethality upon gene ablation and the severe skeletal chondrodysplasia found in these animals [108] . These studies have led to the conclusion that PTHrP in cartilage functions to accelerate the growth of cartilage cells and to oppose their progression to a terminally differentiated cell [109] .
Many features of PTHrP make it an attractive candidate for influencing prostate carcinoma growth. PTHrP is produced by normal prostate epithelial cells, from which prostate carcinoma arises, and PTHrP is found in the seminal fluid [87, 110] . PTHrP has been immunohistochemically identified in prostate carcinoma tissue in patients with clinically localized disease [111] , is found in higher levels in prostate intraepithelial neoplasia than in normal prostate epithelium, is found in higher levels in prostate carcinoma than in benign prostatic hyperplasia [112, 113] [114] suggesting that PTHrP acts in autocrine or intracrine mechanisms to promote tumor growth. In contrast, in this same model and in an intracardiac injection model of prostate carcinoma, PTHrP was not associated with an increase in metastatic potential [83, 114] . This suggests that PTHrP is not important in the process of metastasis to bone but once in the bone microenvironment where target cells with receptors are present (osteoblasts); it may play a critical role in the bone response to prostate carcinoma. Of particular interest to prostate carcinoma, PSA has been shown to cleave PTHrP leading to an inactivation of the PTHrP-stimulation of cAMP which is a key pathway for the actions of PTHrP in bone [123] . More recent studies indicate that in colon cancer cells, PTHrP enhances adhesion of cells to type I collagen but not fibronectin or laminin [124] . All these data suggest that PTHrP has a critical role in the local bone microenvironment of metastatic prostate carcinoma; but what this precise role is has yet to be determined.
Endothelin-1
ET-1 is a member of the ET family which is composed of ET-1, -2, and -3. The ET family members are synthesized as a 203 amino acid precursor peptide that is cleaved to a 21 amino acid peptide with the same two characteristic disulfide bridges [125] . Initially identified as a potent vasoconstrictor, ET-1 interacts with cell surface ET A [136] ). The ectopic expression of ET-1 in the bone metastatic site by prostate carcinoma cells may enable ET-1 to influence the bone remodeling process locally. This is supported by the report that para-tibial injection of an amniotic cell line overexpressing ET-1 induced new bone formation in the tibiae of mice, which was diminished by blockade of ET A receptor [137] . Additionally, administration of an ETA receptor antagonist diminished breast cancerinduced bone production in a murine model [138] . Furthermore, co-incubating the androgen-independent prostate carcinoma cell lines DU-145 and PC-3, but not the androgen-responsive cell line LNCaP, with bone slices induced ET-1 expression from the prostate carcinoma cells [103] . The DU-145 and PC-3 cell lines also induced osteoclastogenic activity that was blocked by anti-human ET-1 antibody. Taken together, these reports suggest that ET-1 may contribute to prostate carcinoma metastases-induced osteoblastic lesions. In apparent conflict with these models, is the observation that serum ET-1 levels are elevated in people with Paget's disease, which is characterized by low bone mineral density secondary to increased osteoclastic activity [139] .
Bone morphogenetic proteins
BMPs are members of the transforming growth factor (TFG)-β superfamily. More than 30 BMPs have been identified to date [140] . While originally discovered because of their ability to induce new bone formation, BMPs are now recognized to perform many functions, particularly in the role of development, such as apoptosis, differentiation, proliferation and morphogenesis (as reviewed in [141] [142] [143] ). BMPs are synthesized as large precursor molecules that undergo proteolytic cleavage to release the mature protein, which form active hetero-or homodimers [144, 145] . BMPs bind to receptors (BMPR-IA and -IB) and a BMP type II receptor (BMPR-II), which induces Smad phosphorylation [146] resulting in modulation of gene regulation. Target genes of BMPs include osteoblast proteins such as OPG [147] and the osteoblast-specific transcription factor Cbfa-1 [148, 149] . Several proteins that antagonize BMP action have been identified. For example, noggin and gremlin inhibit BMP-2, -4 and -7 by binding to them [150] [151] [152] . Furthermore, the BMPs themselves regulate their own inhibitors in an apparent negative feedback mechanism [153, 154] .
Many in vitro studies have demonstrated that BMPs induce osteogenic differentiation including the ability of BMP-7 (also called osteogenic protein-1; OP-1) to induce osteogenic differentiation of newborn rat calvarial cells and rat osteosarcoma cells [155] [156] [157] . The BMPs' osteogenic properties appear to be specific to the differentiation stage of the target cells. Specifically, BMPs can induced uncommitted stem cells [155, 158, 159] and myoblasts [160] to express osteoblast parameters such as alkaline phosphatase or osteocalcin expression [79, 161] ; whereas, BMPs do not stimulate mature osteoblasts or fibroblasts [158, [162] [163] [164] to increase expression of these proteins. Examination of genetically modified mice provides further evidence of the importance of BMP in bone development. The bmp7 homozygous null condition in mice is a postnatal lethal mutation and is associated with, in addition to renal and ocular abnormalities, retarded skeletal ossification [165] . In contrast, bmp6 null mice are viable and fertile, and the skeletal elements of newborn and adult mutants are indistinguishable from wildtype [166] . However, careful examination of skeletogenesis in late gestation embryos reveals a consistent delay in ossification strictly confined to the developing sternum. Finally, mice with mutations of the bmp5 gene have skeletal abnormalities and inefficient fracture repair [167] . Taken together, these data provide evidence that BMPs are important regulators of the osteogenesis. Thus, dysregulation of their expression in the bone microenvironment would most likely impact bone remodeling.
A few studies have examined the expression of BMPs in normal and neoplastic prostate tissues. Using Northern analysis, Harris et al. [92] examined BMP-2, -3, -4 and -6 mRNA expression in human normal prostate and prostate carcinoma cell lines. They found that normal human prostate predominantly expressed BMP-4. The androgen-dependent non-metastatic LNCaP human prostate carcinoma cell line produced very low to undetectable levels of BMPs. Whereas, the aggressive androgen-independent PC-3 cell line expressed very high levels of BMP-3 and slightly lower levels of BMP-2, -4 and -6 compared to normal cells, but much higher than LNCaP cells. In support of these results, Weber et al. [168] , using PCR analysis, identified 16 (73%) of 22 prostate carcinoma samples that were positive for BMP-7 mRNA compared to eight (57%) of 14 normal prostate tissue samples. In another PCR based analysis, Bentley et al. [169] , found that several BMPs were expressed in both benign and malignant prostate tissue and in the PC3 and DU145 prostate carcinoma cell lines. BMP-6 expression was detected in the prostate tissue of over 50% of patients with clinically defined metastatic prostate adenocarcinoma, but was not detected in non-metastatic or benign prostate samples. In another study focused on BMP-6 mRNA and protein expression, Barnes et al. [170] observed that BMP-6 was produced by normal and neoplastic human prostate (radical prostatectomy specimens and human carcinoma cell lines DU145 and PC3). However, BMP-6 mRNA and protein expression was higher in prostate carcinoma as compared with adjacent normal prostate, with higher-grade tumors (Gleason score of 6 or more) having greater BMP-6 immunostaining than the lower-grade tumors (Gleason score of 4 or less). These results were consistent with a later study by Hamdy et al. [171] , who reported that BMP-6 mRNA expression was detected exclusively in malignant epithelial cells in 20 of 21 patients (95%) with metastases, in 2 of 11 patients (18%) with localized cancer, and undetectable in 8 benign samples. In addition to BMP, there have been several reports that prostate carcinoma expresses BMP receptors. It appears that as prostate carcinoma progress, the cells down-regulate their own expression of BMP receptors [172, 173] , which may be a protective mechanism as it has been demonstrated that BMP-2 can inhibit prostate carcinoma cell proliferation [174] . Taken together, these observations demonstrate that prostate carcinoma cells produce increasing levels of BMPs as they progress to a more aggressive phenotype and suggest that the up-regulation of BMP expression in prostate carcinoma cells localized in the bone is a critical component of the mechanism of development of osteoblastic lesions at prostate carcinoma metastatic sites.
The effect of prostate carcinoma on the bone: Osteolytic
Although the osteoblastic component of prostate carcinoma metastases has received attention, limited research has been performed on the osteoclastic aspect of prostate carcinoma. Similar to the reports for breast cancer bone metastases [175, 176] , several lines of evidence suggest that resorption of bone is an important mediator of prostate carcinoma bone metastases. For example, administration of bisphosphonates, inhibitors of osteoclast activity, to patients with prostate carcinoma bone metastases relieves bone pain and lowers systemic indices of bone resorption [177] [178] [179] . Furthermore, administration of osteoclast inhibitors such as OPG or bisphosphonates prevents tumor establishment or diminished tumor burden in animal models [76, [180] [181] [182] . It is not clear if bisphosphonates have a direct antitumor effect [183] [184] [185] or inhibit tumor growth through its ability to diminish osteoclast activity [186, 187] . In some instances, it may be a combination of activities. As described above, in addition to serum levels of bone resorption markers being elevated in men with prostate carcinoma skeletal metastases, the lesions usually are demonstrated to have histological evidence of osteoclast activity. Thus, osteoclast activity may play an important role in development and progression of prostate carcinoma metastases. Prostate carcinoma cells secrete a variety of factors that may promote bone lysis, such as interleukin-6 (as reviewed in [188] ) and PTHrP. However, it appears that these factors mediate their osteolytic effects through induction of a key pro-osteoclastogenic molecule, receptor activator of NFκB ligand (RANKL).
Receptor activator of NFkB ligand-OPG axis
A member of the tumor necrosis factor family, RANKL is initially expressed as a membrane anchored molecule; however, a small fraction of RANKL is released through proteolytic cleavage from the cell surface as a soluble 245 amino acid homotrimeric molecule (sRANKL) [189] . Both soluble and membrane bound RANKL promote osteoclast formation and activation by binding to RANK on the osteoclast precursor membrane [189] [190] [191] [192] [193] . In addition to RANKL and RANK, another key modulator of osteoclastogenesis is osteoprotegerin (OPG)(also known as osteoclastogenesis inhibitory factor-OCIF) [102, 194] . OPG serves as a decoy receptor that binds RANKL and thus blocks its ability to bind to RANK and induce osteoclastogenesis. In contrast to RANKL and RANK, whose expression is mainly restricted at low levels to the skeletal and immune systems, OPG is expressed in a variety of tissues, such as liver, lung, heart, kidney, stomach, intestines, skin and calvaria in mice and lung, heart, kidney and placenta in human [102, [195] [196] [197] [198] [199] [200] [201] . In bone, OPG is mainly produced by osteoblastic lineage cells and its expression increases as the cells become more differentiated [199, 202, 203] . Administration of recombinant OPG to normal rodents resulted in increased bone mass [102, 196] and completely prevented ovariectomy-induced bone loss without apparent adverse skeletal and extraskeletal side effects [102] . In fact, based on this activity, the balance ratio of RANKL to OPG appears to be very important in controlling the overall activity (i.e., lysis vs no lysis) that will be observed [204] [205] [206] .
A number of reports have shown that osteoclastic bone resorptive lesions are important to the development of bone metastases in several cancer types including breast cancer, lung cancer and prostate carcinoma [207] . These cancers may induce osteoclast activity through secretion of IL-1α, PTHrP or PGE2 [208, 209] . However, tumor-mediated osteolysis occurs indirectly through expression of molecules, such as PTHrP, that induce RANKL in osteoblasts [210, 211] . This contrasts with the observations that giant cell tumors directly promote osteoclast activity via RANKL [212] and our observation that prostate carcinoma cells directly induce osteoclastogenesis through RANKL [76] . Another factor that may play a role in tumorinduced osteoclastogenesis is human macrophage inflammatory protein-1α (hMIP-1α), which has been shown to be produced by myeloma cells [213] . Because of the osteoclastic activity induced by many cancers, antiresorptive approaches such as administration of bisphosphonates or anti-PTHrP neutralizing antibody have been reported in breast cancer animal models to be able to block the tumor expansion in bone [214, 215] .
Furthermore, OPG has been recently shown to inhibit primary bone sarcoma-induced osteolysis and tumorinduced bone pain, but not tumor burden in mice [100] . However, OPG not only blocked osteolytic bone metastasis induced by human neuroblastoma NB-19 cells [216] , but also reduced tumor burden in that model. In addition to OPG, a soluble form of RANK (sRANK) has been shown to inhibit myeloma-induced lytic lesions in murine models [217] .
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are family of enzymes whose primary function is to degrade the extracellular matrix. MMPs contribute to metastatic invasion, including destruction of bone [218] . Prostate carcinomas and their cell lines express a large number of MMPs [219] [220] [221] [222] [223] [224] [225] [226] . The initial functional data in prostate carcinoma bone metastasis that suggested bone remodeling is modulated through MMPs was provided by in vitro studies. Specifically, blocking MMP activity with 1,10-phenanthroline, a MMP inhibitor, diminished bone matrix degradation induced by PC-3 cells in vitro [227, 228] . The importance of MMPs in bone metastasis has been further confirmed in vivo. An MMP inhibitor, batimistat, has been shown to inhibit development bone resorption in vitro and in vivo in murine models of breast [229] and prostate carcinoma [230] . The mechanism through which prostate carcinoma-produced MMPs induce bone resorption is not clear; however, it appears to involve induction of osteoclastogenesis as inhibition of MMPs reduced the number of osteoclasts associated with prostate tumor growth in human bone implants in mice [230] .
Conclusions
A model summarizing the cross-talk between prostate carcinoma and the bone microenvironment that leads to development and progression of prostate carcinoma skeletal metastases is presented in Figure 1 . The bone contributes many aspects of the metastatic cascade including chemotaxis, endothelial attachment, invasion and tumor proliferation. Once in the bone microenvironment, the prostate carcinoma cells modulate bone remodeling which favors tumor progression. The presence of many different active factors produced by both the bone and the prostate carcinoma cells that appear to contribute to the pathobiology of skeletal metastases Figure 1 . Model of cross-talk between prostate carcinoma cells and the bone microenvironment. The bone produces chemotactic factors that attract prostate carcinoma cells to migrate (1) through the vascular system towards the skeleton. The bone marrow endothelia displays adhesion molecules that complement those expressed by the prostate carcinoma cell, resulting in attachment of the cell (2) . The prostate carcinoma cell extravasates and invades into the skeletal extracellular tissue (3), at which point it releases factors that stimulate osteoclastogenesis (4). The subsequent bone resorption is accompanied by release of growth factors that stimulate prostate carcinoma proliferation (5). The progressing prostate carcinoma releases factors that promote osteoblast production and inhibit osteoblast apoptosis (6) resulting in production of woven bone and the characteristic osteosclerotic lesion. This process continues in a cyclical fashion with continued induction of osteoclastic activity, carcinoma cell proliferation and bone production.
suggests that defining the mechanisms of prostate carcinoma skeletal metastases will be challenging. Continued research on how these interactions occur may lead to identification of targets to interrupt this crosstalk and prevent the establishment or progression of prostate cancer skeletal metastases. 
